Gouvernement du CanadaSanté Canada/Health Canada
   
Sauter toute navigation -touch directe z Sauter au menu vertical -touch directe x Sauter au menu principal -touch directe m  
English Contactez-nous Aide Recherche Site du Canada
Accueil - ASPC Centres Publications Lignes directrices Index A-Z
Santé - enfants Santé - adultes Santé - aînés Surveillance Santé Canada
   
    Agence de santé publique du Canada
Relevé des maladies transmissibles au Canada

 

Relevé des maladies transmissibles au Canada
Volume 29 DCC-4
le 15 août 2003

Une déclaration d'un comité consultatif (DCC)
Comité consultatif national de l'immunisation (CCNI)*†

DÉCLARATION SUR LA VACCINATION ANTIGRIPPALE POUR LA SAISON 2003-2004

Document Adobe télédéchargeable
20 pages - 290 KB PDF

Voir aussi :
MISE À JOUR : DÉCLARATION SUR LA VACCINATION ANTIGRIPPALE
POUR LA SAISON 2003-2004

Références

  1. British Columbia Centre for Disease Control. Epilogue: China airlines passengers' illness due to influenza, not SARS. URL: <http://www.bccdc.org/downloads/pdf/epid/reports/
    SARSUpdate_ChinaAirlines_may02-03a.pdf    >. 

  2. Organisation mondiale de la Santé. Composition recommandée des vaccins antigrippaux pour la saison 2003-2004. Relevé épidémiologique hebdomadaire 2003;78:58-62. 

  3. Organisation mondiale de la Santé. Maladies transmissibles : surveillance et action. URL: <http://www.who.int/emc/diseases/flu/country.html>. 

  4. Kilbourne ED, Arden NH. Inactivated influenza vaccines. Dans : Plotkin SA, Orenstein WA, éds. Vaccines. Philadelphie : W.B. Saunders Co., 1999;539.

  5. Shortridge KF. SARS exposed, pandemic influenza lurks. Lancet 2003;361:1649.

  6. Centers for Disease Control and Prevention. Recommendations to enhance US surveillance for influenza A (H5N1). URL: <http://www.cdc.gov/ncidod/disease/ flu/hanH5N1.htm>.

  7. Abbott A. Chicken flu races through Dutch poultry farms. Nature 2003;422:247.

  8. Centers for Disease Control and Prevention. Human cases of avian influenza A (H7N7) infection, the Netherlands, 2003. URL: <http://www.cdc.gov/ncidod/diseases/flu/h7n7/facs.htm>.

  9. Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind placebo-controlled trial. Ann Intern Med 1999;131:430-33. 

  10. Fine AD, Bridges CB, De Guzman AM et coll. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 2001;32:1784-91. 

  11. Kroon FP, van Dissel JP, de Jong JC et coll. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000;18:3040-49. 

  12. Zanetti AR, Amendola A, Besana S et coll. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 2002;20(5):B29-32.

  13. Uyeki TM, Zane SB, Bodnar UR et coll. Large summertime influenza A
    outbreak among tourists in Alaska and the Yukon Territory.     Clin Infect Dis 2003;36(9):1095-1102.

  14. Brotherton JM, Delpech VC, Gilbert GL et coll. A large outbreak of influenza A and B on a cruise ship causing widespread morbidity. Epidemiol Infect 2003;130(2):263-71. 

  15. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2003;52(RR-8);1-34. 

  16. Potter J, Stott DJ, Roberts MA et coll. Influenza vaccination of health-care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997:175;1-6. 

  17. Wilde JA, McMillan JA, Serwint J et coll. Effectiveness of influenza vaccine in health care professionals. A randomized trial. JAMA 1999;281:908-13. 

  18. Boersma B, Rhames T, Keegan JM. Additional cost savings of an effective employee influenza program on prevention of nosocomial influenza. Am J Infect Control 1999;27:177-78. 

  19. Orr P. Influenza vaccination for health care workers: a duty of care. Can J Infect Dis 2000;11(5):225-6. 

  20. Herwaldt LA. Greek philosophy, medical ethics, and the influenza vaccine. Infect Control Hosp Epidemiol 1993;14:15-16. 

  21. Rea E, Upshur R. Semmelweis revisited: the ethics of infection prevention among health care workers. Can Med Assoc J 2001;164(10):1447-48. 

  22. Nguyen-Van-Tam J, Granfield R, Pearson J et coll. Do influenza epidemics affect patterns of sickness absence among British hospital staff? Infect Control Hosp Epidemiol 1999;20:691-94. 

  23. Centers for Disease Control and Prevention. General recommendations for preventing influenza infection among travelers. URL: <http://www.cdc.gov/travel/other/h5n1apr2004.htm>. 

  24. Mixeu MA, Vespa GNR, Forleo-Neto E et coll. Impact of influenza vaccination on civilian aircrew illness and absenteeism. Aviat Space Environ Med 2002;73:876-80. 

  25. Bridges CB, Thompson WW, Meltzer MI et coll. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000;284:1655-63. 

  26. Demicheli V, Jefferson T, Rivetti D et coll. Prevention and early treatment of influenza in healthy adults. Vaccine 2000;18:957-1030. 

  27. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001;161:749-59. 

  28. Grotto I, Mandel Y, Green MS et coll. Influenza vaccine efficacy in young, healthy adults. Clin Infect Dis 1998;26:913-17. 

  29. Saxen H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 1999;18:779-83. 

  30. White T, Lavoie S, Nettleman MD. Potential cost saving attributable to influenza vaccination of school-aged children. Pediatrics 1999;103:e73. 

  31. Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics 2000;106:973-76. 

  32. Dayan GH, Nguyen VH, Debbag R et coll. Cost-effectiveness of influenza vaccination in high-risk children in Argentina. Vaccine 2001;19:4202-13. 

  33. Lee PY, Matchar DB, Clements DA et coll. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002;137:225-31. 

  34. Jefferson T, Demicheli V. Economic analysis of influenza vaccination and treatment [Letter]. Ann Intern Med 2003;138:607. 

  35. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003;21(16):1769-75. 

  36. Demicheli V. Mass influenza vaccination in Ontario: Is it worthwhile? Can Med Assoc J 2001;164(1):38-9. 

  37. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults (Cochrane Review). Dans : The Cochrane Library, Oxford; issue 2, 2002. 

  38. Ahmed F, Singleton JA, Franks AL. Influenza vaccination for healthy young adults. N Engl J Med 2001;345(21):1543-7. 

  39. Deinhard AS, Ogburn P. A/NJ/8/76 influenza vaccination program: effects on maternal health and pregnancy outcome. Am J Obstet Gynecol 1981;140:240-45.

  40. Freeman DW, Barno A. Deaths from Asian influenza associated with pregnancy. Am J Obstet Gynecol 1959;78:1172-75. 

  41. Collins SD. Age and sex incidence of influenza and pneumonia morbidity and
    mortality in the epidemic of 1928-1929 with comparative data for the epidemic of 1918-1919    . Public Health Rep 1931;46:1909. 

  42. Eickhoff TC, Sherman H, Serfling RE. Observations on excess mortality associated with epidemic influenza. JAMA 1961;176:776. 

  43. Mullooly JP, Barker WH, Nolan TF. Risk of acute respiratory disease among pregnant women during influenza A epidemics. Public Health Rep 1986;101:205-11. 

  44. Neuzil KM, Reed GW, Mitchel EF et coll. Impact of influenza on acute cardiac pulmonary hospitalizations in pregnant women. Am J Epidemiol 1998;148:1094-1102. 

  45. Bedard P-M, Gascon G. Fatal outcome of systemic vasculitis following influenza vaccination. Can J Allergy Clin Immun 1999;4:405-06. 

  46. Tavadia S, Drummond A, Evans CD et coll. Leucocytoclastic vasculitis and influenza vaccination. Clin Exp Dermatol 2003;28(2):154-56. 

  47. Robertson WC. Carbamazepine toxicity after influenza vaccination. Pediatr Neurol 2002;26(1):61-3. 

  48. Lasky T, Terracciano GJ, Magder L et coll. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-802.

  49. McLean M, Duclos P, Jacob P et coll. Incidence of Guillain-Barré syndrome in Ontario and Quebec, 1983-1989, using hospital service databases. Epidemiology 1994;5:443-48. 

  50. Comité consultatif national sur l'immunisation. Déclaration supplémentaire pour la saison 2001-2002 : vaccin antigrippal chez les personnes souffrant du syndrome oculo-respiratoire suite à une vaccination antigrippale antéerieure. RMTC 2001;27(DCC-7):1-7. 

  51. Spila-Alegiani S, Salmaso S, Rota MC et coll. Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Vaccine 1999;17:1898-904. 

  52. Comité consultatif national sur l'immunisation. Déclaration supplémentaire pour la saison grippale 2002-2003 : le point sur le syndrome oculo-respiratoire associé au vaccin antigrippal. RMTC 2002;28(DCC-6):1-8.

  53. Skowronski DM, De Serres G, Hébert J et coll. Skin testing to evaluate oculo-respiratory syndrome (ORS) associated with influenza vaccination during the 2000-2001 season. Vaccine 2002;20:2713-19. 

  54. Scheifele DW, Duval B, Russel ML et coll. Ocular and respiratory symptoms attributable to inactivated split influenza vaccine: evidence from a controlled trial involving adults. Clin Infect Dis 2003;36:850-857. 

  55. De Serres G, Grenier JL, Toth E et coll. The clinical spectrum of the oculo-respiratory syndrome after influenza vaccination. Vaccine 2003;21:2354-61.

  56. Skowronski D, Strauss B, Kendall P et coll. Low risk of recurrence of oculorespiratory syndrome following influenza revaccination. Can Med Assoc J 2002;167(8):853-58. 

  57. De Serres G, Skowronski DM, Guay M et coll. Risk of recurrence of oculo-respiratory syndrome (ORS) associated with two different influenza vaccines for 2002-2003. The Sixth Annual Conference on Vaccine Research, Arlington, VA, 5-7 May 2003, Abstract S33. 

  58. De Serres G, Boulianne N, Duval B et coll. Oculo-respiratory syndrome following influenza vaccination: evidence for occurrence with more than one influenza vaccine. Vaccine 2003;21:2346-53. 

  59. Skowronski DM, De Serres G, Scheifele D et coll. Randomized double-blind placebo controlled trial to assess the rate of recurrence of oculo-respiratory syndrome in persons previously affected following influenza vaccination. Clin Infect Dis 2003;36 (in press). 

  60. Comité consultatif national sur l'immunisation. Vaccin contre l'influenza. Dans : Guide canadien d'immunisation, 5e éd. Ottawa : Santé Canada, 1998:138-46. Cat. No H49-8/2000F.

  61. Duclos P, Arruda H, Dessau JC et coll. Enquête sur l'immunisation de la population adulte non institutionnalisée - Québec (au 30 mai 1996). RMTC 1996;22:177-82.

  62. DeWals P, Carbonneau M, Payette H, Niyonsenga T. Influenza and pneumococcal vaccination in long term care facilities in two regions of Quebec. Can J Infect Dis 1996;7:296-300. 

  63. Stevenson CG, McArthur MA, Naus M et coll. Prevention of influenza and pneumococcal pneumonia in Canadian long-term care facilities: How are we doing? Can Med Assoc J 2001;164(10):1413-19. 

  64. Russell ML. Influenza vaccination in Alberta long-term care facilities. Can Med Assoc J 2001;164(10):1423-27. 

  65. Nichol KL, Hauge M. Influenza vaccination of healthcare workers. Infect Control Hosp Epidemiol 1997;18(3):189-94. 

  66. Evans MR, Watson PA. Why do older people not get immunized against influenza? A community survey. Vaccine 2003;21(19-20):2421-27. 

  67. Centers for Disease Control. Influenza vaccine information for health care personnel. URL: <http://www.cdc.gov/ncidod/hip/flu_vac.htm>.

  68. Hammond GW, Cheang M. Absenteeism among hospital staff during an influenza epidemic: implications for immunoprophylaxis. Can Med Assoc J 1984;131:449-52. 

  69. Yassi A, Kettner J, Hammond G et coll. Effectiveness and cost-benefit of an annual influenza vaccination program for health care workers. Can J Infect Dis 1991;2:101-08. 

  70. Stilianakis NI, Perelson AS, Hayden FG. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis 1998;1977:863-72. 

  71. Drinka PJ, Gravenstein S, Schilling M et coll. Duration of antiviral prophylaxis during nursing home outbreaks of influenza A. Arch Intern Med 1998;158:2155-59.

  72. Aoki F. Amantadine and rimantadine. Dans : Nicholson KG, Webster RG, Hay AJ, éds. Textbook of Influenza. Oxford: Blackwell Science 1998;457-76.

  73. Buxton JA, Skowronski DM, Ng H et coll. Previous creatinine levels safely predict amantadine dose for influenza A outbreak control. Can J Infect Dis 2001;12(5):185-8.

  74. McGeer A, Sitar D, Tamblyn S et coll. Use of antiviral prophylaxis in influenza outbreaks in long term care facilities. Can J Infect Dis 2000;11(4):187-92.

  75. Horadam VW, Sharp JG, Smilack JD et coll. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 1981;94:454-58.

 

[Précédente] [Relevé des maladies transmissibles au Canada]

Dernière mise à jour : 2004-08-30 début
Avis importants